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OBJECTIVE: To develop and validate a self-reported question-
naire to help physicians to select Atrial Fibrillation (AF) patients
eligible for a treatment change in the prevention of Thrombo-
Embolic event (TEE). METHODS: An Advisory Committee (AC)
of 4 specialists was set up. A conceptual model speciﬁc of pre-
vention of TEE in AF patients and treatment switch issues was
derived from literature, 5 cardiologist and 6 AF patient inter-
views. Clinician and patient interviews were conducted using a
semi-structured interview guide covering broad concepts with
open-ended questions. Systematic analysis produced a list of
detailed concepts and then a test questionnaire, which were both
independently validated by the AC. Five cardiologists were asked
to comment on the relevance and comprehensiveness of each item;
5 AF patients completed the questionnaire and were then asked
to provide general comments regarding the questionnaire and
detailed comments regarding each element. A revised question-
naire was produced and then validated by the AC. RESULTS:
The concepts identiﬁed from the literature were: patient expec-
tations, fears and satisfaction; perception of treatment; impor-
tance of patient preference in treatment choice; and inﬂuential
factors for patients in treatment choice. After clinician and patient
interviews, 16 global concepts and 75 detailed concepts were
retained. The test questionnaire included 43 items in 11 sections:
“your illness”, “your anticoagulant treatment”, “expected bene-
ﬁts”, “perceived beneﬁts”, “expected risks”, “perceived risks”,
“biological follow-up”, “visits to the doctor”, “changes to the
anticoagulant treatment”, “constraints”, “changes of treatment”.
Six items were excluded by the AC and 1 was added after the
clinician and patient tests. The pilot questionnaire included 38
items in 11 sections. CONCLUSION: This pilot questionnaire
could help physicians in the choice of treatment and patient man-
agement by taking perceptual and behavioural factors into
account. The questionnaire needs to undergo item reduction,
scoring and validation before use in clinical practice.
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OBJECTIVES: The objective of the literature review was to
describe generic and speciﬁc PRO instruments developed and/or
used in atrial ﬁbrillation. The review focuses 1) on the descrip-
tion of generic and speciﬁc PRO instruments, including Quality
of life, Symptoms, Activities of Daily Living and Patient Satis-
faction and 2) on the use of PRO instruments in clinical trials of
patients with atrial ﬁbrillation. METHODS: A systematic liter-
ature review of published studies was conducted using
MEDLINE (1966–2004), EMBASE (1974–2004) and the Mapi
Research Trust databases. Only studies with named, referenced
PRO instruments used in patients with atrial ﬁbrillation were
reviewed. Based on the review of the domains covered and the
availability of psychometric properties for all the instruments
retrieved, a selection of instruments was further analyzed for
their psychometric properties and their use in randomized clini-
cal trials. RESULTS: Forty-ﬁve PRO instruments have been 
identiﬁed: 18 cardiac-speciﬁc, 17 generic and 10 psychological
instruments. After examination of the domains assessed and the
availability of psychometric properties, 19 of the 45 instruments
were further analyzed. From these 19 instruments, only 5 instru-
ments (2 cardiac-speciﬁc, 2 generic and 1 psychological instru-
ments) were found to have good psychometric properties,
including sensitivity to change in randomized clinical trials.
CONCLUSIONS: Despite the large amount of PRO identiﬁed,
only two cardiovascular disease-speciﬁc instruments were found
to be well validated in patients with atrial ﬁbrillation and to be
responsive to change in randomized clinical trials.
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OBJECTIVES: To examine patterns of pharmacotherapy and
outcomes among patients with chronic heart failure (CHF).
METHODS: We identiﬁed a national cohort of patients with
CHF in the Department of Veterans Affairs (VA) beginning
October 1, 1999 (FY00) and tabulated use of cardiovascular
agents, 1-year all cause and CHF (DRG 127) hospital use and
survival from FY00 through FY02 (September 30, 2002). We
determined health care costs from inpatient, ambulatory and
outpatient pharmacy services, and calculated the relative share
of these costs across VA medical centers. RESULTS: The total
number of patients ranged from 261,054 in FY00 to 299,462 in
FY02. The average age (sd) ranged from 70.1 (10.4) to 71.1
(10.4). Therapeutic classes where use increased included:
angiotensin-converting enzyme (ACE) or angiotensin II
inhibitors (66.7% to 69.3%); beta-blockers (43.2% to 54.0%);
statins (42.0% to 51.9%); and spironolactone (9.7% to 12.0%).
Classes where use decreased included: digitalis (38.1% to
34.1%) and calcium channel blockers (35.7% to 32.4%).
Diuretic use was relatively constant at 73%. All cause and CHF
hospitalization decreased from 26.8% to 22.1% and 5.0% to
4.0%, respectively. One-year mortality decreased from 9.6% to
8.7%. Hospital costs per patient at risk for hospitalization (all
patients) decreased from $4933 to $4268 (2002). The relative
share of costs of care for hospitalization (about half of total
costs) thus decreased overall while costs for ambulatory care and
pharmacy services increased slightly. CONCLUSIONS: Pharma-
cotherapy patterns in the VA exhibited evidence-based practice.
All cause hospitalization, hospitalization for heart failure and
mortality all decreased. Hospitalization costs decreased, result-
ing in a net decline in the cost of health care delivery for these
patients. Findings suggest that provision of good pharmacolog-
ical care is improving outcomes and shifting the costs of care
from inpatient to outpatient pharmacy and ambulatory care.
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